HekaBio K.K. announced today that it has successfully completed a financing round of JPY 400 million. Proceeds will be used to strengthen and expand HekaBio’s portfolio of innovations in development in Japan.
HekaBio specializes in the development and commercialization of innovative therapies originating from overseas, with an initial focus on cancer, fibrotic disease and autoimmune/inflammatory disorders.
Our veteran team leverages its experience and global network developed at two earlier ventures—Junicon K.K., a global medical market research-based consultancy established in Tokyo in 1992, and Vorpal Technologies K.K., a pharmaceutical and medical device CRO established in Tokyo in 2013.
HekaBio K.K. will continue its portfolio expansion and product development based on the company mission to address the unmet needs of patients and medical professionals in Japan.
About HekaBio K.K.
HekaBio’s mission is to connect world-leading healthcare innovations to unmet medical needs in Japan, with broad category development expertise in pharma, medical device, in vitro diagnostics, digital health, and cell & gene therapies. HekaBio targets innovations in oncology, fibrotic disease and autoimmune/inflammation that have a high potential for significant therapeutic benefit and healthcare cost savings.
For more information, visit www.hekabio.com
Contact: Mari Tanaka